State Street Corp Tango Therapeutics, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,866,098 shares of TNGX stock, worth $23.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,866,098

Previous 978,938 192.78%

Holding current value

$23.9 Million

Previous $9.69 Million 134.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.51 - $12.88 $14.2 Million - $24.3 Million	1,887,160 Added 192.78%	2,866,098 $22.8 Million
Q4 2023 Feb 14, 2024	BUY	$6.52 - $12.01 $163,384 - $300,958	25,059 Added 2.63%	978,938 $9.69 Million
Q3 2023 Nov 14, 2023	BUY	$2.93 - $11.26 $160,974 - $618,624	54,940 Added 6.11%	953,879 $10.7 Million
Q2 2023 Aug 14, 2023	BUY	$2.67 - $4.7 $206,684 - $363,827	77,410 Added 9.42%	898,939 $2.98 Million
Q1 2023 May 15, 2023	SELL	$3.76 - $8.06 $83,998 - $180,060	-22,340 Reduced 2.65%	821,529 $3.25 Million

Q4 2022 Feb 14, 2023	SELL	$3.41 - $8.29 $97,979 - $238,196	-28,733 Reduced 3.29%	843,869 $6.12 Million
Q3 2022 Nov 15, 2022	BUY	$3.25 - $5.46 $423,364 - $711,252	130,266 Added 17.55%	872,602 $3.16 Million
Q2 2022 Aug 15, 2022	BUY	$3.86 - $8.01 $1.91 Million - $3.97 Million	495,202 Added 200.38%	742,336 $3.36 Million
Q1 2022 May 16, 2022	BUY	$7.01 - $10.94 $120,158 - $187,522	17,141 Added 7.45%	247,134 $1.87 Million
Q4 2021 Feb 14, 2022	BUY	$9.55 - $14.29 $304,578 - $455,750	31,893 Added 16.1%	229,993 $2.52 Million
Q3 2021 Nov 15, 2021	BUY	$9.56 - $17.3 $1.89 Million - $3.43 Million	198,100 New	198,100 $2.56 Million

Others Institutions Holding TNGX

# of Institutions

127

Shares Held

88.8M

Call Options Held

Put Options Held

1.6K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $734M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Tango Therapeutics, Inc. Transaction History